ten Bokkel Huinink W, Veenhof C, Huizing M, Rodenhuis S, Helmerhorst T, Dubbelman R, Dalesio O, Beijnen J, Winograd B
The Netherlands Cancer Institute, Academic Medical Center, Amsterdam.
Semin Oncol. 1997 Feb;24(1 Suppl 2):S2-31-S2-33.
Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) combined with cisplatin seems the new standard of care for ovarian cancer patients. Since carboplatin lacks the neurotoxicity of cisplatin with an equal antitumor activity against ovarian cancer, it was chosen as the next logical step for combination chemotherapy with paclitaxel. In 46 patients an alternating dose-escalation trial has been performed. The maximum tolerated doses are carboplatin 500 mg (area under the concentration-time curve of 9) and paclitaxel 200 mg/m2 given every 3 weeks. The dose-limiting toxicity is thrombocytopenia, which emerges in the later stages of the treatment. A true platelet-sparing effect of the combination seems highly probable. The antitumor activity of the combination equals that reported for the new standard paclitaxel/cisplatin treatment. Further phase III studies are warranted.
紫杉醇（泰素；百时美施贵宝公司，新泽西州普林斯顿）联合顺铂似乎是卵巢癌患者新的治疗标准。由于卡铂缺乏顺铂的神经毒性且对卵巢癌具有同等的抗肿瘤活性，因此它被选为与紫杉醇联合化疗的下一个合理步骤。对46例患者进行了交替剂量递增试验。最大耐受剂量为卡铂500毫克（浓度-时间曲线下面积为9）和紫杉醇200毫克/平方米，每3周给药一次。剂量限制性毒性为血小板减少症，出现在治疗后期。该联合用药似乎极有可能产生真正的血小板保护作用。该联合用药的抗肿瘤活性与新的标准治疗方案紫杉醇/顺铂所报道的相当。有必要进行进一步的III期研究。
